Starling Oncology Inc(STLN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:33 PM ET (Korea 10/23 05:33)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.31 | Insider Own | 29.95% | Shs Outstand | 100.5M | Perf Week | - |
| Market Cap | 0.69B | Forward P/E | - | EPS next Y | 100% | Insider Trans | -0.67% | Shs Float | 70.0M | Perf Month | 1.32% |
| Enterprise Value | 0.75B | PEG | - | EPS next Q | -0.05 | Inst Own | 37.13% | Short Float | 9.7% | Perf Quarter | 38.76% |
| Income | -0.03B | P/S | 1.18 | EPS this Y | 69.91% | Inst Trans | 5.51% | Short Ratio | 4.9 | Perf Half Y | 111.31% |
| Sales | 0.59B | P/B | - | EPS next 5Y | - | ROA | -18.06% | Short Interest | 6.79M | Perf YTD | 94.1% |
| Book/sh | -0.25 | P/C | 16.81 | EPS past 3/5Y | -37.23% -17.58% | ROE | -3407.86% | 52W High | -3.09% ($7.13) | Perf Year | 57.4% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | 25.81% 21.8% | ROIC | -42.21% | 52W Low | 197.84% ($2.32) | Perf 3Y | 345.81% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 54.91% | Gross Margin | 14.54% | Volatility(W/M) | 6.73% 5.82% | Perf 5Y | -30.55% |
| Dividend TTM | - | EV/Sales | 1.28 | Sales Y/Y TTM | 38.38% | Oper. Margin | -4.44% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.15 | EPS Q/Q | 46.7% | Profit Margin | -5.2% | RSI (14) | 56.77 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.36 | Sales Q/Q | 34.62% | SMA20 | 5.4% ($6.56) | Beta | 0.46 | Target Price | $9.75 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | 7.05% ($6.45) | Rel Volume | 0.63 | Prev Close | $6.83 |
| Employees | 641 | LT Debt/Eq | - | EPS/Sales Surpr. | -25% 3.56% | SMA200 | 49.69% ($4.62) | Avg Volume(3M) | 1.39M | Price | $6.91 |
| IPO | 2020/6/4 | Option/Short | Yes/Yes | Trades | 5571 | Volume | 868,583 | Change | 1.17% |
� A healthcare facility company that operates a network of community-based cancer treatment clinics across the United States. It pursues a value-based care model by delivering specialty treatments such as oncology services, clinical trials, and infusions at clinics near where patients live, and has expanded its clinics and network care sites across multiple states.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded less than usual. That is 63% of its average volume.
STLN has a sound balance sheet but weak earning power
Of every $100 in sales, $4.44 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +69.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $118. Peers typically go for $98.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -30.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 37.1%.
Tap to view numbers
It ranks #32 of 48 in the industry
Based on market cap of $691M.
STLN#32 Starling Oncology Inc $691M PER - 
GMRS#33 GMR Solutions Inc $582M PER - 
SRTA#34 Strata Critical Medical Inc $418M PER - 
CYH#35 Community Health Systems Inc $410M PER 1.6 
AUNA#36 Auna SA $372M PER 92.1 
FAQ
What kind of company is STLN?
STLN belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of STLN?
The market cap of STLN is approximately $691M, ranking 2,876 within its sector.
What is the 52-week high and low for STLN?
STLN has recorded a 52-week high of $7.13 and a low of $2.32.
